Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.

Détails

Ressource 1Télécharger: serval:BIB_5EE756EA6CCB.P001 (281.59 [Ko])
Etat: Public
Version: de l'auteur
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_5EE756EA6CCB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
Périodique
American journal of hypertension
Auteur(s)
Maillard M.P., Mazzolai L., Daven V., Centeno C., Nussberger J., Brunner H.R., Burnier M.
ISSN
0895-7061
Statut éditorial
Publié
Date de publication
1999
Peer-reviewed
Oui
Volume
12
Numéro
12 Pt 1-2
Pages
1201-8
Langue
anglais
Notes
Publication types: Clinical Trial ; Comparative Study ; Journal Article ; Randomized Controlled Trial - Publication Status: ppublish
Résumé
An in vitro angiotensin II (AngII) receptor-binding assay was developed to monitor the degree of receptor blockade in standardized conditions. This in vitro method was validated by comparing its results with those obtained in vivo with the injection of exogenous AngII and the measurement of the AngII-induced changes in systolic blood pressure. For this purpose, 12 normotensive subjects were enrolled in a double-blind, four-way cross-over study comparing the AngII receptor blockade induced by a single oral dose of losartan (50 mg), valsartan (80 mg), irbesartan (150 mg), and placebo. A significant linear relationship between the two methods was found (r = 0.723, n = 191, P<.001). However, there exists a wide scatter of the in vivo data in the absence of active AngII receptor blockade. Thus, the relationship between the two methods is markedly improved (r = 0.87, n = 47, P<.001) when only measurements done 4 h after administration of the drugs are considered (maximal antagonist activity observed in vivo) suggesting that the two methods are equally effective in assessing the degree of AT-1 receptor blockade, but with a greatly reduced variability in the in vitro assay. In addition, the pharmacokinetic/pharmacodynamic analysis performed with the three antagonists suggest that the AT-1 receptor-binding assay works as a bioassay that integrates the antagonistic property of all active drug components of the plasma. This standardized in vitro-binding assay represents a simple, reproducible, and precise tool to characterize the pharmacodynamic profile of AngII receptor antagonists in humans.
Mots-clé
Angiotensin II, Antihypertensive Agents, Biological Markers, Biphenyl Compounds, Blood Pressure, Cross-Over Studies, Double-Blind Method, Humans, Hypertension, Losartan, Radioligand Assay, Receptor, Angiotensin, Type 1, Receptor, Angiotensin, Type 2, Receptors, Angiotensin, Reproducibility of Results, Tetrazoles, Valine, Vasoconstrictor Agents
Pubmed
Web of science
Open Access
Oui
Création de la notice
05/03/2008 17:40
Dernière modification de la notice
25/09/2019 7:09
Données d'usage